Alberta Investment Management Corp Purchases 2,400 Shares of AbbVie Inc. $ABBV

Alberta Investment Management Corp boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 8.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 31,000 shares of the company’s stock after purchasing an additional 2,400 shares during the period. Alberta Investment Management Corp’s holdings in AbbVie were worth $7,178,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Evolution Wealth Management Inc. purchased a new position in AbbVie during the second quarter worth about $26,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. purchased a new position in shares of AbbVie during the second quarter worth about $36,000. Delos Wealth Advisors LLC bought a new position in shares of AbbVie in the second quarter worth approximately $39,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in AbbVie in the third quarter valued at approximately $41,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on ABBV. BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a research note on Thursday, January 15th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Citigroup lowered their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday, January 27th. JPMorgan Chase & Co. increased their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Finally, Evercore cut their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $251.56.

AbbVie Stock Down 1.7%

ABBV opened at $228.79 on Thursday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a market capitalization of $404.36 billion, a price-to-earnings ratio of 96.95, a PEG ratio of 0.81 and a beta of 0.35. The firm has a 50 day moving average price of $224.01 and a 200-day moving average price of $221.68.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.